Meplyffa (arimoclomol)

Where it stands

Meplyffa (arimoclomol), from Zevra Denmark A/S, received a CHMP negative opinion on 23 July 2026 in the EU. The records list its status as Refused and show no approval date. The proposed indication was treatment of Niemann-Pick disease type C (NPC) in patients aged 6 months and older, in combination with miglustat.

The records give no grounds for the negative opinion. They do not say which aspects of the dossier, such as efficacy, safety or quality, the committee found insufficient. Any reading of the reasons has to wait for the published assessment documentation.

The records also list the same substance under the name Miplyffa in the EU, with the status Application withdrawn. They give no dates or reasons for that withdrawal and do not explain how the two entries relate, so no link between them should be assumed.

Regulatory pathway and designations

The product carries an Orphan designation, and the therapeutic area is Niemann-Pick Diseases. The only milestone in the records is the CHMP negative opinion of 23 July 2026, which is marked official. The records do not show the submission date, the review timetable, or any clock-stops, oral explanations or other procedural steps.

As general procedure, a negative CHMP opinion goes to the European Commission for a decision, and a refusal means the product cannot be marketed in the EU under a central authorisation. Under EU rules, an applicant can ask for re-examination of a negative opinion within a set period after receiving it. The records do not say whether Zevra has done so or intends to.

Orphan designation gives access to incentives such as protocol assistance and fee reductions. Market exclusivity applies only once a product is authorised. With a refusal, the exclusivity benefit does not arise. The records give no detail on the orphan designation itself, such as its date or its status on the register.

Safety and pharmacovigilance

The records contain no safety data. They include no adverse event information, risk management plan, or pharmacovigilance commitments, and they do not say whether safety played a part in the negative opinion.

Because the product is not authorised in the EU, no EU post-authorisation pharmacovigilance obligations follow from this record. Safety and benefit-risk reasoning, if published, would appear in the assessment report that accompanies the refusal.

What to watch

The first item is whether Zevra requests re-examination of the opinion. The second is the publication of the CHMP assessment report and the refusal's stated grounds, which would show whether the issues could be addressed with new data or analyses. The records do not indicate either step has happened.

Also worth watching are the formal European Commission decision and any update to the orphan register entry. Teams should also clarify the relationship between the Meplyffa and Miplyffa entries, since the records show one refused and one withdrawn without explanation.

The records say nothing about the product's status outside the EU. Any view on the wider development programme would need other sources.